Exaggerated platelet aggregation at the site of vascular injury is the underlying pathophysiology of thrombotic diseases. Here, we conduct the largest whole genome sequencing (WGS) effort to uncover the genetic determinants of platelet aggregation. Leveraging 3,855 NHLBI Trans-Omics for Precision Medicine (TOPMed) individuals deeply phenotyped for platelet aggregation, we identify 18 loci using single-variant approaches. This includes the novel RGS18 locus encoding a myeloerythroid lineage-specific regulator of G-protein signaling that co-localizes with eQTL signatures for RGS18 expression in platelets. A gene-based approach focusing on deleterious coding variants identifies the SVEP1 gene, previously shown to be associated with coronary artery disease, as a novel determinant of platelet aggregation. Finally, in an integrative approach leveraging epigenetic data on megakaryocytes, we find strong association between rare variants mapping to a super enhancer region for PEAR1. This is a novel finding implicating the importance of rare variants with regulatory potential in a previously documented GWASidentified locus.
Platelet aggregation at the site of atherosclerotic vascular injury is the underlying pathophysiology of myocardial infarction and stroke 1 . Identification of the factors that contribute to increased platelet reactivity is critical to understanding the biology of arterial thrombus formation and in the development of novel treatment strategies for patients at risk for pathologic vascular thrombosis. Here, we conduct the largest whole genome sequencing (WGS) effort to uncover the genetic determinants of platelet aggregation by leveraging 3,855 NHLBI Trans-Omics for Precision Medicine (TOPMed) participants deeply phenotyped for platelet aggregation. Using single-variant approaches, we identify 16 independent loci including the novel RGS18 locus, which encodes a myeloerythroid lineage-specific regulator of G-protein signaling that co-localizes with expression quantitative trait loci (eQTL) signatures for RGS18 expression in platelets. Additionally, a gene-based approach focusing on deleterious coding variants identifies the SVEP1 gene, a known contributor of coronary artery disease risk, as a novel determinant of platelet aggregation. Finally, in an integrative approach leveraging epigenetic data on megakaryocytes (MK), we observe strong association between rare variants mapping to a super-enhancer region for PEAR1 and platelet aggregation. Together, these results unveil novel loci contributing to platelet reactivity, provide insights regarding the mechanism(s) by which genetic variation may influence cardiovascular disease risk, and underscore the importance of utilizing rare variant and regulatory approaches to better understand loci contributing to complex phenotypes.
Previous studies have shown that platelet aggregation in response to agonists is highly heritable [2] [3] [4] [5] [6] and prior genome-wide association studies (GWAS) have identified 7 common variants for platelet aggregation in response to different agonists. [7] [8] [9] Using a WGS approach, we aimed to i) refine previously identified GWAS loci; ii) identify novel loci; iii) examine the burden of deleterious coding variants; and iv) evaluate rare non-coding variants within MK-specific superenhancer regions for 19 harmonized phenotypic measures of platelet aggregation in response to different doses of adenosine diphosphate (ADP), epinephrine, and collagen (Supplementary Figure 1) . We identified 101 variants associated with platelet aggregation in response to ADP, epinephrine, or collagen (P-value<5x10 -8 , Figure 1 ). Using iterative conditional analyses, genome-wide significant variants were refined down to 16 independent loci ( Table 1) . With the exception of two variants (rs12041331 and chr17:21960955) all of these loci were uniquely associated with platelet aggregation in response to one agonist, and most of the identified loci were novel ( Supplementary Figure 2) . Replication of discovery findings was performed in up to 2,009 additional samples imputed to the TOPMed reference panel that were not in the discovery analyses (Supplementary Table 3a) , and extended to the Caerphilly Prospective Study [CaPS] (N=1,183) for ADP and collagen-induced platelet aggregation phenotypes 8, 10 (Supplementary Table 4 ).
Given that all of the 16 loci identified using single-variant approaches are located in non-coding regions of the genome, we tested for co-localization between these regions and eQTL data available through RNA sequencing of platelets in 180 European Americans from GeneSTAR (Supplementary Table 5 ). We found that sentinel variants in the PEAR1 and RGS18 loci were eQTLs for PEAR1 and RGS18, respectively. Furthermore, co-localization signatures for PEAR1 and RGS18 were identified using Bayesian approaches (Figure 2) . Previous work demonstrated a single, common (~14% MAF) intronic peak variant in PEAR1 (rs12041331) is associated with platelet phenotypes using GWAS, regional sequencing, and exonic approaches 8, [11] [12] [13] . The minor allele of rs12041331 is linked to decreased PEAR1 platelet protein levels 13, 14 , potentially through alteration of a methylation site in MKs 15 . In addition, the role of this gene in platelet signaling is supported by mechanistic studies 16, 17 . Our co-localization results with platelet eQTLs are consistent with a model that a single, common causal variant explains the platelet reactivity signal. While results of previous association studies on PEAR1 variants and coronary disease are mixed [18] [19] [20] [21] , UK BioBank 22 data supports an association (Supplementary Table 6 ).
In the novel RGS18 region, several variants were replicated using independent samples imputed with the TOPMed panel (Supplementary Table 3) , and independent evidence was also found for ADP and collagen aggregation phenotypes in the CaPS study (Supplementary Table 4 ).
Overlaying the associated variants with platelet eQTLs and megakaryocytic epigenome features, there are several potential candidate variants (Supplementary Table 7) . Consistent with our human results, independent Rgs18 -/-mouse studies suggest Rgs18 inhibits pre-agonist stimulated platelet reactivity, with knockouts exhibiting exaggerated platelet reactivity to multiple agonist pathways, decreased bleeding times, and increased arterial occlusion 23, 24 . This is attributed to a loss of inhibition of multiple G-protein coupled receptor signaling pathways in platelets 25 .
Notably, variants in RGS18 identified in our study are also associated with altered risk for cerebral infarction and subarachnoid hemorrhage in the UK BioBank (Supplementary Figure 3 ) with significant findings after Bonferroni correction for SVEP1 (ADP-induced platelet aggregation, P-value=2.6x10 -6 ), BCO1 (epinephrine-induced platelet aggregation, P=8.9x10 -7 ),
NELFA (collagen-induced platelet aggregation, P=1.7x10 -6 ) and IDH3A (collagen-induced platelet aggregation, P-value=2.6x10 -6 ). Using a leave-one-out analysis, we observed that these associations were driven mainly by single or limited sets of rare variants (Supplementary Figure  4, Supplementary Table 9 ). For example, the SVEP1 association with ADP-induced platelet aggregation was solely driven by a nonsynonymous variant (Gly229Arg) in the second exon (rs61751937, MAF 0.028, P-value=5.8x10 -6 ). This variant alters a highly conserved residue located in the protein's VWFa domain (Figure 3a-c) . The finding replicated in the WGS imputed cohorts (P-value =0.004) and CaPS (P-value=0.008) demonstrating an association with increased ADP-induced platelet reactivity. Interestingly, a different variant in SVEP1, rs111245230, is associated with hypertension and increased cardiovascular risk in an exome study 27 . This variant is in linkage equilibrium (r 2 =0.0002; D'=0.01) with our peak variant and not associated with ADP-induced platelet aggregation (P=0.06). Both variants are modestly associated with CVD outcomes in the UK BioBank (Supplementary Table 10 ). Collectively, these results suggest that SVEP1 may have previously unappreciated and multifactorial roles in contributing to CVD. Homozygous Svep1 -/-mice die from edema, and heterozygous mice, as well as zebrafish, experience arterial and lymphatic vessel malformations [28] [29] [30] . Consistent with previous investigations 31 , RNAseq data in a subset of GeneSTAR participants do not indicate expression of SVEP1 in platelets. The protein is strongly conserved (Figure 3c ) and could potentially affect platelet function and CVD through several mechanisms including cell-cell adhesion, cell differentiation, and functions in bone marrow niches 32 .
To investigate the role of genetic variation on regulatory importance in the context of superenhancers, we aggregated rare non-coding variants across a set of 1,065 published MK-specific super-enhancers (Supplementary Figure 5) 33 . We found rare non-coding variants in a superenhancer at the PEAR1 locus was significantly associated with ADP-(P=2.4x10 -8 ), epinephrine-(P-value=1.1x10 -7 ) and collagen-(P-value=2.7x10 -5 ) induced platelet aggregation. We observed, in marked contrast to our gene-based coding variant analyses, that the association signal in the PEAR1 super-enhancer is driven by multiple rare variants in the region (Supplementary Figure  6) .
In this first WGS study of platelet aggregation, we identify and replicate several novel loci contributing to trait variation. Among the 16 identified independent variants, 7 were associated with wide range of blood-related traits including CVD outcomes in a phenome-wide association study using UK Biobank data (Supplementary Table 6 ). While population genetic and genomic studies remain limited in size for platelet function traits, our results indicate the potential for novel discoveries made through sequencing approaches in deeply phenotyped individuals which may ultimately relate to CVD risk and treatment efficacy. This is underlined by data supporting the hypothesis that hyper-reactive platelets may predict future thromboses in both healthy, untreated individuals 34 and those who have already experienced thrombosis 35, 36 , as well as the fact that antiplatelet therapy remains standard of care in secondary prevention of atherothrombotic diseases such as myocardial infarction and stroke. Using a leave-one-out approach, we identified a rare coding variant (rs61751937) that explains most of the association. First orange dot represents the overall gene based test including 64 variants. Subsequent orange dots represent the -Log10(P-value) of the gene based test when the specific labeled variant was left out, and blue bars represent minor allele frequency (MAF) of specific variant being left out. 3b. Schematic protein structure of SVEP1. rs61751937 substitutes glycine for arginine at position 229. Another variant in SVEP1 has been associated with coronary artery disease which substitutes glycine for aspartic acid at position 2702. 3c. Using UniProt, a total of 98 orthologs were identified for the largest human SVEP1 protein isoform and aligned. Alignments were visualized in MAFFT (v.7, https://mafft.cbrc.jp/alignment/server/, Katoh et al. 2017 ) 37 with ClustalW coloring. Both amino acids 229G and 2702D are highly conserved across diverse species, as well as their surrounding protein domains. 
